Selected Publications

Developmental Signaling in Cancer

Vasudevan et al. Cell Reports (2018)

Vasudevan HN, Braunstein SE, Phillips JJ, Pekmezci M, Tomlin BA, Wu A, Reis GF, Magill ST, Zhang J, Feng FY, Nicholaides T, Chang SM, Sneed PK, McDermott MW, Berger MS, Perry A, Raleigh DR. Comprehensive molecular profiling identifies FOXM1 as a key transcription factor for meningioma proliferation. Cell Reports. 2018. 22:3672-3683. PMID: 29590631.

Raleigh DR, Sever N, Choksi PK, Sigg MA, Hines KM, Thompson BM, Elnatan D, Jaishankar P, Bisignano P, Bisignano P, Garcia-Gonzalo FR, Eamon B, Choksi S, Krup AL, Eberl M, Wong SY, Renslo A, Siebold C, Grabe M, McDonald JG, Xu L, Beachy PH, Reiter FR. Cilia-associated oxysterols activate Smoothened. Mol Cell. 2018. 72:316-327. PMID: 30340023. 

Raleigh DR, Choksi PK, Krup AL, Santos N, Reiter JR. Hedgehog signaling drives medulloblastoma growth via CDK6. J Clin Invest. 2017. Epub ahead of print. PMID: 29202464.

Garcia G, Raleigh DR, Reiter JR. Organizing inside-out to communicate outside-in: how the ciliary membrane is specialized for signaling. Curr Biol. 2018. 23:R421-R434. PMID: 29689227. 

Raleigh DR, Algazi A, Arron ST, Neuhaus IM, Yom SS. Induction hedgehog pathway inhibition followed by combination modality radiotherapy for basal cell carcinoma. Br J Dermatol. 2015. 173:544-546. PMID: 25702621.



Raleigh et al. Mol Cell (2018)

Chen WC, Hara J, Magill ST, Wu A, Aghi MK, Theodosopoulos, PV, Perry A, McDermott MW, Sneed PK, Raleigh DR*, Braunstein SE*. Salvage therapy outcomes for atypical meningioma. J Neuro Oncol. 2018. Epub ahead of print. PMID: 29480505. *Authors contributed equally. 

Chen WC, Magill ST, Wu A, Vasudevan HN, Morin O, Aghi MK, Theodosopoulos PV, Perry A, McDermott, MW, Sneed PK, Braunstein SE, Raleigh DR.Histopathologic features predictive of local control of atypical meningioma after surgery and adjuvant radiotherapy. J Neurosurg2018. Epub ahead of print. PMID: 29624151. 

Vasudevan HN*, Raleigh DR*, Johnson J, Garsa AA, Theodosopoulos PV, Aghi MK, Ames C, McDermott MW, Barani IJ, Braunstein SE. Management of chordoma and chondrosarcoma with fractionated stereoetactic radiotherapy. Neurosurg Focus. 2017. 23;4:35. PMID: 28691010. *Authors contributed equally. 

Kline CN, Joseph NM, Grenert JP, van Ziffle J, Talevich E, Onodera C, Aboian M, Cha S, Raleigh DR, Braunstein SE, Torkildson J, Samuel D, de Alba Campomanes A, Banerjee A, Butowski N, Raffel C, Tihan T, Bollen AW, Phillips JJ, Korn M, Yeh I, Bastian BC, Gupta N, Mueller S, Perry A, Nicolaides T, Solomon DA. Targeted next-generation sequencing of pediatric brain tumor patients improves diagnosis, identified pathogenic germline mutations, and directs targeted therapy. Neuro Oncol. 2017. 19:699-709. PMID: 27978508. 

Raleigh DR, Tomlin B, Del Buono B, Roddy E, Sear K, Byer L, Felton E, Banerjee A, Torkildson J, Samuel D, Horn B, Braunstein SE, Haas-Kogan DA, Mueller S. Survival after chemotherapy and stem cell transplant followed by delayed craniospinal irradiation is comparable to upfront craniospinal irradiation in pediatric embryonal brain tumor patients. J Neurooncol. 2017. 131:359-368. PMID: 27778212. 

Raleigh DR, Seymour ZA, Tomlin B, Theodosopoulos PV, Berger MS, Aghi MK, Geneser SE, Krishnamurthy D, Fogh SE, Sneed PK, McDermott MW. Resection and brain brachytherapy with permanent iodine-125 seeds for brain metastasis. J Neurosurg. 2017. 126:1749-1755. PMID: 27367240.

Garcia MA, Lazar A, Duriseti S, Raleigh DR, Hess C, Fogh SE, Barani IJ, Nakamura JL, Larson DA, Theodosopoulos P, McDermott MW, Sneed PK, Braunstein SE. Discovery of additional brain metastases on the day of stereotactic radiosurgery: risk factors and outcomes. J Neurosurg. 2017. 126:1756-1763. PMID: 27367235. 

Raleigh DR*, Solomon DA*, Lloyd SA, Lazar A, Garcia MA, Sneed PK, Clarke JL, McDermott MW, Berger MS, Tihan T, Haas-Kogan DA. Histopathologic review of pineal parenchymal tumors identifies novel morphologic subtypes and prognostic factors for outcome. Neuro Oncol. 2017. 19:78-88. PMID: 27282397. *Authors contributed equally. 

Magill ST, Lau D, Raleigh DR, Sneed PK, McDermott MW. Surgical resection and interstitial 125I brachytherapy for high grade meningioma: a 25-year series. Neurosurg. 2017. 80:409-416. PMID: 27258768.  

Kaprealian K*, Raleigh DR*, Sneed PK, Nabavizadeh N, Nakamura JL, McDermott MW. Parameters influencing local control of meningiomas treated with radiosurgery. J Neurooncol. 2016. 128:357-364. PMID: 27131883. *Authors contributed equally. 

Vaubel R, Chen S, Raleigh DR, Link M, Chicoine M, Barani IJ, Jenkins S, Aleff PA, Rodriguez F, Burger PC, Dahiya S, Perry A, Giannini C. Meningiomas with focal rhabdoid features lacking other histologic features of malignancy: a study of 44 cases and review of the literature. J Neuropathol Exp Neurol. 2016. 75:44-52. PMID: 26705409.

Menke JR, Raleigh DR, Gown AM, Thomas S, Perry A, Tihan T. Somatostatin receptor 2a is a more robust immunohistochemical marker of meningioma than epithelial membrane antigen. Acta Neuropathol. 2015. 130:441-443. PMID: 26195322.


Genomic Stress

Crawley CD, Kang S, Bernal GM, Wahlstrom JS, Voce DJ, Cahill KE, Garofalo A, Raleigh DR, Weichselbaum RR, Yamini B. S-phase-dependent p50/NF-κB1 phosphorylation in response to ATR and replication stress acts to maintain genomic stability. Cell Cycle. 2015. 14: 566-576. PMID: 25590437.

Crawley CD*, Raleigh DR*, Kang S, Voce DJ, Schmitt AM, Weichselbaum RR, Yamini B. DNA damage-induced cytotoxicity is mediated by the cooperative interaction of phospho-NF-κB and a single nucleotide in the κB-site. Nucl Acids Res. 2013. 41:764-774. PMID: 23180782. *Authors contributed equally. 

Schmitt AM, Crawley CD, Kang S, Raleigh DR, Yu X, Wahlstrom JS, Voce DJ, Darga TE, Weichselbaum RR, Yamini B. p50 (NF-κB1) is a novel effector protein in the cytotoxic response to DNA methylation damage. Mol Cell. 2011. 44:785-796. PMID: 22152481.


Epithelial Biology

Raleigh DR, Boe DM, Yu D, Weber CR, Marchiando AM, Bradford EM, Wang Y, Wu L, Schneeberger EE, Shen L, Turner JR. Occludin S408 phosphorylation regulates tight junction protein interactions and barrier function. J Cell Biol. 2011. 193:565-582. PMID: 21536752.

Shen L, Weber CR, Raleigh DR, Turner JR. Tight junction pore and leak pathways: A dynamic duo. Annu Rev Phys. 2011. 73: 283-309. PMID: 20936941.

Yu D, Marchiando AM, Weber CR, Raleigh DR, Wang Y, Shen L, Turner JR. MLCK regulates tight junction barrier function via the ZO-1 actin binding region: In vitro, in vivo, and in silico analysis. Proc Natl Acad Sci USA. 2010. 107:8237-8241. PMID: 20404178.

Marchiando AM, Shen L, Graham WV, Weber CR, Schwarz BT, Austin JR, Raleigh DR, Guan Y, Watson Alastair JM, Montrose MH, Turner JR. Caveolin-1-dependent occludin endocytosis is required for TNF-induced tight junction regulation in vivo. J Cell Biol. 2010. 189:111-126. PMID: 20351069. Featured article and cover art.

Weber CR, Raleigh DR, Su L, Shen L, Sullivan EA, Wang Y, Turner JR. Epithelial myosin light chain kinase activation induces mucosal interleukin-13 expression to alter tight junction ion selectivity. J Biol Chem. 2010. 285:12037-12046. PMID: 20177070.

Raleigh DR, Marchiando AM, Zhang Y, Shen L, Sasaki H, Wang Y, Long M, Turner JR. Tight junction-associated MARVEL proteins marvelD3, tricellulin, and occludin have distinct but overlapping functions. Mol Biol Cell. 2010. 21:1200-1213. PMID: 20164257. Featured article and cover art.


Click here for a complete list of publications.